Patient Preferences With Pharmaceutical Care: In-person Versus Digital Health

October 2, 2023 updated by: Georges Hatem, Lebanese University

A Cross-sectional Study Addressing Lebanese Patient Preferences With Pharmaceutical Care: Traditional Versus Digital Health?

Digital pharmaceutical care, also known as e-pharmaceutical care or telepharmacy, refers to using digital technologies to provide remote pharmaceutical care services. It involves the application of digital tools and platforms to deliver medication-related services, patient counseling, medication management, and other pharmaceutical care activities. It allows patients to access pharmaceutical services conveniently from their homes or any location with an internet connection. This is particularly beneficial for individuals with limited mobility, those living in rural or underserved areas, or patients with difficulty visiting a physical pharmacy. However, it is essential to note that while digital pharmaceutical care provides many benefits, it may only suit some patients or situations. Some individuals may still prefer face-to-face interactions or may require hands-on assistance, especially for complex medication management. Healthcare providers should assess the appropriateness of digital solutions on a case-by-case basis and ensure patient privacy and data security when implementing digital pharmaceutical care services.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

386

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beirut, Lebanon, 0000
        • Pharmacy Du Liban
    • Mount Lebanon
      • Beirut, Mount Lebanon, Lebanon, 0000
        • Pharmacy Bouchi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Adult individuals who visited two community pharmacies during the data collection period. No criteria were based on sex, race, nationality, or ethnicity.

Description

Inclusion Criteria:

  • Patients who took at least one medication in the past month
  • Patient visiting two community pharmacies

Exclusion Criteria:

  • Those refusing to participate
  • Those with severe hearing or mental problems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patient
Convenient sampling of patients who took at least one medication in the past month
Developed questionnaire to assess the literacy of patients + another survey to assess their preferences regarding traditional versus digital pharmaceutical care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient preference
Time Frame: through study completion, an average of 2 months
A self-reported questionnaire was developed and piloted on the first 30 patients visiting the pharmacies. Minor modifications were performed taking into consideration two expert reviews. It is available in Arabic (native language) and English based on participants' preferences. It includes 3 parts: the first part comprises the baseline characteristics of the patients and their medical history/habits; the second part reports patients' preferences, benefits and disadvantages of each of the outcomes (in-person versus digital health); and the third part assess e-literacy among them using the e-HEALS 8-item scale previously validated on the Arab population.
through study completion, an average of 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2023

Primary Completion (Actual)

October 1, 2023

Study Completion (Actual)

October 1, 2023

Study Registration Dates

First Submitted

August 3, 2023

First Submitted That Met QC Criteria

August 11, 2023

First Posted (Actual)

August 21, 2023

Study Record Updates

Last Update Posted (Actual)

October 3, 2023

Last Update Submitted That Met QC Criteria

October 2, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 12/23/D

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe